⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11210690 | 0.71 | — | — | |
| SCHEMBL790462 | 0.69 | — | — | |
| SCHEMBL790461 | 0.69 | — | — | |
| SCHEMBL790565 | 0.69 | — | — | |
| SCHEMBL13207548 | 0.69 | — | — | |
| SCHEMBL23280419 | 0.69 | ALDH1A1 (0.33) | — | |
| SCHEMBL11696159 | 0.67 | — | — | |
| SCHEMBL11696165 | 0.67 | — | — | |
| SCHEMBL19557142 | 0.65 | — | — | |
| SCHEMBL21736947 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345713-B2 | Compounds as modulators of TLR2 signaling | NEUROPORE THERAPIES, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210024539-A1 | COMPOUNDS AS MODULATORS OF TLR2 SIGNALING | NEUROPORE THERAPIES, INC. (US) | 2021-01-28 | — | — | US | disclosed |